Zoetis develops and sells medicines, vaccines, diagnostics, and veterinary technology for companion animals and livestock. Its portfolio includes parasiticides, dermatology treatments, pain management, antibiotics, animal vaccines, and diagnostic instruments and tests. Revenue comes from veterinarians, animal hospitals, producers, and distributors, with pet care and livestock health providing different demand drivers.
Zoetis Inc. (ZTS) has a MarketKingdoms composite score of 51.2 (C), an C-range rating. It ranks 1710th of 1,866 covered companies, 77th of 78 in Healthcare (sector average 64.4) and 6th of 6 in Drug Manufacturers - Specialty & Generic. Scores as of 2026-10-26.
Its strongest lenses are Industry opportunity at 74 (Healthcare average 81) and Quality (profitability) at 74 (Healthcare average 50). Its weakest lenses are Trend (momentum) at 9 (sector average 50) and Expansion (growth) at 14 (sector average 50).
| Lens | Type | ZTS | Healthcare average | Drug Manufacturers - Specialty & Generic average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 74 | 81 | 74 | 15th |
| Stock selection | Research signal | 58 | 79 | 76 | 3rd |
| KPI momentum | Research signal | 29 | 78 | 71 | 1st |
| Catalyst watch | Research signal | 71 | 74 | 71 | 19th |
| Price (valuation) | Fundamental lens | 70 | 50 | 65 | 82nd |
| Expansion (growth) | Fundamental lens | 14 | 50 | 39 | 4th |
| Quality (profitability) | Fundamental lens | 74 | 50 | 63 | 85th |
| Trend (momentum) | Fundamental lens | 9 | 50 | 48 | 8th |
The most recent call analysed was held on 2026-08-06 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -2.7%: its price is in line with the path its market, sector and industry moves explain. Factor sensitivity: market beta 0.41, sector beta 1.00, industry beta -0.17; the factor model explains 22% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Ironwood Pharmaceuticals Inc. (IRWD) | 76.7 | A- | -66.6% |
| Viatris Inc. (VTRS) | 63.8 | B- | -13.1% |
| Teva Pharmaceutical Industries Ltd. ADR (TEVA) | 63.5 | B- | -29.4% |
| United Therapeutics Corp. (UTHR) | 62.7 | B- | -10.5% |
| Haleon plc ADR (HLN) | 60.7 | B- | +4.3% |
Zoetis Inc. financial statements · Healthcare sector ranking · Drug Manufacturers - Specialty & Generic industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.